CLINICAL_TRIALS ClinicalTrials.gov record update

Post-marketing Observational Study of Remitoro® Intravenous Injection 300 μg - Safety of Remitoro in Patients With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05137847
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:25.552505+00:00
Published At: 2023-12-12T00:00:00+00:00
Record Updated At: 2023-12-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, T-cell, Peripheral", "Lymphoma, T-cell, Cutaneous"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-12"
protocolSection.identificationModule.nctId: "NCT05137847"
protocolSection.identificationModule.officialTitle: "Post-marketing Observational Study of Remitoro\u00ae Intravenous Injection 300 \u03bcg - Safety of Remitoro in Patients With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.